| Trial ID: | L3016 |
| Source ID: | NCT00372086
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Rosiglitazone and Insulin in T1DM Adolescents
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 1 Diabetes|Puberty: >Tanner 2 Breast Development or Testis >4ml
|
| Interventions: |
DRUG: Rosiglitazone
|
| Outcome Measures: |
Primary: HbA1c | Secondary: insulin dose|frequency of severe hypoglycaemia|insulin sensitivity assessed by euglycaemic, hyperinsulinaemic clamp|weight|BMI-SDS|skin fold thickness|cholesterol|adiponectin
|
| Sponsor/Collaborators: |
Sponsor: The University of New South Wales | Collaborators: Sydney Children's Hospitals Network|National Health and Medical Research Council, Australia|Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
32
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2003-08
|
| Completion Date: |
2005-09
|
| Results First Posted: |
|
| Last Update Posted: |
2006-09-06
|
| Locations: |
Sydney Children's Hospital, Sydney, New South Wales, 2038, Australia
|
| URL: |
https://clinicaltrials.gov/show/NCT00372086
|
